Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 13/20 | 0.71 |
| ▸ | S100A4 | P26447 | 5/20 | 0.71 |
| ▸ | MAP2K7 | O14733 | 3/20 | 0.65 |
| ▸ | CDC25A | P30304 | 3/20 | 0.65 |
| ▸ | CDC25B | P30305 | 3/20 | 0.65 |
| ▸ | STAT3 | P40763 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7106792 | 0.83 | SOAT1 (1.00) | SOAT1S100A4MAP2K7CDC25ACDC25B | |
| SCHEMBL2599403 | 0.83 | S100A4 (1.00) | SOAT1S100A4MAP2K7CDC25ACDC25B | |
| SCHEMBL9270311 | 0.81 | S100A4 (0.76) | SOAT1S100A4MAP2K7CDC25ACDC25B | |
| SCHEMBL2599427 | 0.80 | SOAT1 (1.00) | SOAT1S100A4MAP2K7CDC25ACDC25B | |
| SCHEMBL9267240 | 0.80 | S100A4 (0.69) | SOAT1S100A4MAP2K7CDC25ACDC25B | |
| SCHEMBL2599351 | 0.79 | S100A4 (1.00) | SOAT1S100A4MAP2K7CDC25ACDC25B | |
| SCHEMBL15732841 | 0.79 | SOAT1 (1.00) | SOAT1S100A4MAP2K7CDC25ACDC25B | |
| SCHEMBL2599376 | 0.79 | SOAT1 (1.00) | SOAT1S100A4MAP2K7CDC25ACDC25B | |
| SCHEMBL10034769 | 0.79 | P4HB (0.70) | S100A4STAT3 | |
| SCHEMBL15732984 | 0.78 | SOAT1 (1.00) | SOAT1S100A4MAP2K7CDC25ACDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773111-B1 | Selective 5-LO inhibitors for the treatment of bronchial asthma | King Faisal University (SA) | 2023-10-03 | — | — | US | disclosed |
| US-11724991-B1 | Selective 5-LO inhibitors for the treatment of bronchial asthma | King Faisal University (SA) | 2023-08-15 | — | — | US | disclosed |
| US-20150192852-A1 | LITHOGRAPHIC PRINTING PLATE PRECURSOR AND PLATE MAKING METHOD | FUJIFILM CORPORATION (JP) | 2015-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773111-B1 | Selective 5-LO inhibitors for the treatment of bronchial asthma | ALOX5, LTC4S, NOX5 | SOAT1 1139/4885S100A4 4476/4885MAP2K7 921/4885 |
| US-11724991-B1 | Selective 5-LO inhibitors for the treatment of bronchial asthma | ALOX5, LTC4S, NOX5 | SOAT1 1175/4885S100A4 4257/4885MAP2K7 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.